The ability of human V.3 immunoglobulins (Ig) to bind to staphylococcal protein A (SPA) via their Fab region is analogous to the binding of bacterial superantigens to T cell receptors. The present report establishes the structural basis for the interaction of SPA and V.3 Ig. We have studied a panel of 27 human monoclonal IgM that were derived from fetal B lymphocytes. As such, these IgM were expected to be encoded by unmutated germline genes. Binding to SPA in ELISA occurred with 15 of 15 V.3 IgM, but none of 12 IgM from the V.1, V.4, V.5, or V.6 families. The V. sequences of the 27 IgM were derived from 20 distinct V. elements, including 11 from the V.3 family. Use of D, J., and CL genes was similar among V.3 and non-V.3 IgM. A comparison of the corresponding V. protein sequences, and those of previously studied IgM, identified a probable site for SPA binding that includes V~3 residues in framework region 3 (FR3), and perhaps FR1 and 3' complementary determining region 2. The results thus demonstrate that among human IgM, specificity for SPA is encoded by at least 11 different V.3 germline genes. Furthermore, like the T cell superantigens, SPA likely binds to residues in the V. framework region, outside the classical antigen-binding site of the hypervariable loops.
S
taphylococcal protein A (SPA) possesses Ig Fab-binding sites specific for determinants on the V region of the Ig H chain. These "alternative binding site(s)" of SPA are distinct from its well-characterized IgG Fc-binding sites (1) (2) (3) . We previously demonstrated that the ability oflg Fab to bind to SPA is a functional marker for Ig encoded by the largest human V. gene family, V.3 (4) . Furthermore, SPA binding was seen with nearly all tested V.3 IgM, and with a large portion of the tested V.3 IgA, and V.3 IgG F(Ab')2 fragments (4, 5) . These findings suggested that specificity for SPA is encoded by the germline sequences of many of the commonly expressed V~3 genes. The data also implied, as did studies of SPA-binding mouse Ig (6) , that the Fab site to which SPA binds involves V. family-specific residues, most of which have been demonstrated to reside outside the conventional antigen-binding site (7) (8) (9) . This association of V.3 H chains with specificity for SPA is analogous to the ability of certain TCR Va molecules to bind bacterial superantigens (10) . Therefore, we proposed that SPA, which is a potent polyclonal activator of human B cells, be considered an Ig superantigen (5) .
To further examine the structural basis for the interaction between V.3 Ig and SPA, we have now studied the SPAbinding properties and VH sequences of 27 monoclonal IgM derived from fetal B lymphocytes. The IgM were encoded by a spectrum of V. elements, all of which are probably unmutated germline genes. We found that all V. 3 IgM, but none of the other IgM, bound to SPA. Comparison of the IgM V~ sequences identified a surface containing residues of framework region 1 (FK1), 3'CDR2, and FK3, that likely has a role in SPA binding. The data also suggested that a determinant for SPA binding exists among V,3 residues 75 to 84, in FK3. It is concluded that IgM specificity for SPA is encoded by at least 11 V~3 germline genes, and that SPA likely binds to a V~3 framework region, outside the classical Ag-binding site.
Materials and Methods
Monoclonal B Cell Lines. Mononuclear cells were isolated by density gradient centrifugation from second trimester fetal liver and spleen provided by the University of Washington Central Laboratory for Human Embryology (11) . Fetal mononuclear cells were transformed by EBV and cloned by limiting dilution, as previously described (12) . Studies described below were performed with 26 lines, randomly selected from among 62 IgM-producing cell lines (12) . Beg-2, a human heterohybridoma generated from fetal spleen cells, was kindly provided by Dr. Richard Watts (University College, London, England).
Determinaron of lgM Concentration and L Chain Isotype. Supernatants of the 27 monoclonal IgM cell lines were assayed by ELISA in 96-well trays coated with goat F(ab')2 anti-human F(ab')2 (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA). L chain isotype was determined by detecting bound IgM with goat F(ab')2 anti-human K and goat F(ab')2 anti-human X, both conjugated with horseradish peroxidase (Cooper Biomedical, Malvern, PA). IgM concentration was determined by detecting bound Ig with horseradish peroxidase--conjugated goat F(ab')z anti-human IgM, Fc.-specific (Cooper Biomedical), and comparing results with a standard curve prepared with purified polyelonal human IgM (Calbiochem Novabioehem, La Jolla, CA). For subsequent binding studies, every supernatant was adjusted to >10.1 #g lgM/ml in tissue culture media (IMDM; Sigma Chemical Co., St. Louis, MO) that was supplemented with 10%o FCS, 2 mM L-glutamine, 50 U/ml penicillin, and HAT (Boehringer Mannheim, Indianapolis, IN). All supernatants were shown to be devoid of human IgG by detection with horseradish peroxidase-conjugated Fc-specific goat F(ab')2 anti-human IgG.
IgM (12) . The cDNA was then amplified by the PCR with the addition of a primer representing a consensus sequence in V. codons I to 8 (5'-CAGGTGCAGCTGGTGAATTCTGG-3') (12). PCIL product was ligated into Puc18 and sequenced by conventional methods (13, 14) . Each reported sequence represents a consensus of sequences from at least two independent cDNA, each of which was sequenced the entire reported length. Nucleotide mismatches occurred at a rate of one per 10,000 bp. (Fig. 1) . In contrast, binding to SPA was not seen with any of the nine IgM from the V,1 family, or the IgM from the V.4, V.5, or V.6 families (one each) ( Binding to SPA by 27 fetally derived monoclonal IgM. ELISA wells were coated with SPA, washed, incubated with test IgM in supernatant at 0.1/zg/ml, washed, then incubated with horseradish peroxidase-conjugated goat F(ab')2 anti-human IgM, followed by ABTS substrate. Binding levels are the mean of two simultaneous measurements, expressed in OD units. IgM are grouped by V. gene family. Genetic elements identify previously reported V. and J. germline genes to which the obtained IgM sequences are 100% identical, and previously reported D. germline genes to which the obtained IgM sequences are identical over at least 6 bp. Novel elements were <98% identical to reported germline genes. The germline origin of short D. regions could not be determined. CL isotype was determined by ELISA anal-),sis of the respective IgM clone, which is named in the fifth column. The V. sequences 13-2a and 20p3a differ by a single base pair from 13-2 and 20p3, respectively, but appear to be distinct germline elements because the 13-2a and 20p3a sequences were each recovered from >1 independent rearrangements (Hillson, J. L., unpublished data). References for the named genes include 56pl, 51p1, 20p3, V.6 (15), 1.9111, 13-2, 22-21~ 5-1RI (16) , 301969 (17) , 26c (18) , 287 0-lillson, J. L., unpublished data), J. dements (19) , and D. elements (8, (19) (20) (21) (22) (23) (24) Fig. 2) . Comparison of these protein sequences identified 23 positions at which the amino acid residue is invariant among the V.3 sequences and different from the residue(s) present in the V.1 sequences. At position 82a also, the V.3 residues are identical, and different from the V.1 residues, except for a conservative substitution in one V.3 sequence, 3Gll (Fig. 2) .
Results
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We have determined the SPA-binding ability and the V. did not demonstrate Fab-mediated binding to SPA (4, 5) . The elements encoding these SPA-nonbinding V~3 Ig could have lost specificity for SPA through somatic modification, or they might belong to a subset of V.3 germline genes that encode SPA-nonbinding proteins. It is also possible that certain combinations of D, J., V~, and JL genes abrogate V.3 binding to SPA. However, the broad variety of these genes (D, J., VL, JL) that have been found to encode SPA-binding IgM argues that this effect occurs infrequently, if at all (4, 28, 30) . The site on Ig Fab that binds to SPA has been localized to the variable region of the H chain (31) , and shown to be functionally distinct from a conventional hapten-binding site (32) . Our data now provide structural evidence that SPA binds outside the classical antibody binding site. The V. sequences from our IgM identify 24 amino acid positions at which all V.3 sequences have a conserved residue, and all V.1 sequences differ by a nonconservative change. Two of these positions are in FR2, which is inaccessible to solvent (8) . The remaining 22 positions localize a candidate binding site for SPA to two peptides, one in FR1 (residues 9-27), the other in 3' CDR2/FR3 (residues 62-84). Seven of these positions, indicated at the bottom of Fig. 2 (X) , are strongly associated with IgM ability to bind to SPA, because their V.3 residues are unique. The other 15 positions, (x), could also have a role in SPA binding, even though their V.3 amino acids appear in the V.6 sequence (13 of 15 positions), the V.4 sequence (12 positions), or the V.5 sequence (5 positions). In an intact, folded Ig molecule, the two peptides reside in closely adjacent, solvent-exposed, ~/-pleated sheets that define a region on the lateral aspect of the Fab molecule that is removed from the V. hypervariable loops (8) (Fig. 3) . This 9". structure is structurally analogous to the region bound by T cell superantigens on the fl chain of TCRs (33, 34) .
Further insight into the protein A-binding site of V.3 Ig can be gained by examining six previously reported V. sequences, from IgM Pom, Lay, Riv, KL1, SJ1, and TS2 (Fig.  2) (25-27) , IgM Pore, Lay, Riv, and KL1 bind to SPA (4, 28) . In contrast, IgM SJ1 and TS2 have been reported to not bind to SPA (28) , even though their protein sequences are 94 and 96% identical, respectively, to those encoded by 1.9III and 56pl, which we found to bind to SPA (Fig. 1) . A sequence comparison that includes SJ1 and TS2 identifies five FR3 positions, 75, 76, 80, 82a, and 84, at which nonconservative substitutions in a V.3 sequence are associated with inability to bind protein A (Fig. 2) . Each of these positions was also identified by the above analysis of our V~3 sequences (Fig. 2) . Thus, some of these substitutions could have abrogated SPA binding. The other substitutions in SJ1 and TS2 are unlikely to have abrogated SPA binding because, either (a) they resulted in a conservative amino acid change (residues 28 in FR1, and 59 in CDR2); (b) they occurred at a site that is inaccessible to SPA (residue 40 in FR2); or (c) in other V.3 IgM, nonconservative substitutions at that position were associated with retained ability to bind SPA (residues 52, 52a, and 57 in CDR2) (Fig. 2) .
These findings suggest that the FR3 75-84 peptide conrains a determinant that is critical for binding to SPA. Residues 75-84 begin in a FR3 loop, and extend to include a portion of FR3 that is nearer to the C region than to the CDR (Fig.  3) . Among residues 75-84, nonconservative substitutions that do not abrogate SPA binding are found in IgM KL1 (T to P, residue 77); Lay (R to Q, residue 83); and Pore (Q to I and R to Q, residues 81 and 83) (Fig. 2) . It seems likely, therefore, that only a limited number of residues in the 75 to 84 peptide is directly involved in the SPA-V.3 interaction. This prediction can be directly tested by site-directed mutagenesis.
In conclusion, we have studied the SPA-binding properties of a panel of monoclonal human IgM produced by B lymphocytes derived from fetal liver or spleen. Binding occurred with all V.3 molecules, but no others, indicating that specificity for SPA is encoded by at least 11 different VH3 germline genes. Analysis of IgM V. sequences indicated that conserved residues in VH3 FR1 and 3' CDR2/FR3 likely play a role in SPA recognition by V~3 proteins. Furthermore, the site to which SPA binds might directly involve residues in the FR3 75-84 peptide. These findings elucidate the structural basis of the nonclassical binding specificity that V.3 Ig have for SPA, and demonstrate a structural analogy between the SPA-Fab interaction, and the binding of bacterial superantigens to TCRs.
